Mr. John Price reports

TELO GENOMICS ANNOUNCES $250,000 TERM LOAN FACILITY

Telo Genomics Corp. has closed a term loan agreement, effective Oct. 29, 2026, with BrightArc Capital Adminco 1 Inc., for a principal amount of $250,000.

The term loan is a demand non-revolving facility. The company has received an initial advance of $100,000, with the balance of the term loan to be advanced at a later date. Interest accrues at a simple rate of 1.30 per cent per month (equivalent annual rate of 15.60 per cent), payable monthly in arrears. A minimum of three months of interest is payable if the term loan is repaid within three months of advance. The facility is secured by a general security agreement over the company's present and after-acquired personal property (with specific reference to scientific research and experimental development claims) and an irrevocable assignment of the company's SR&ED tax credits and refunds. Proceeds are to be used to finance the company's general operating expenses.

The outstanding balance (principal, accrued interest and other amounts) is due on the earlier of: (i) three business days after the company receives its SR&ED claims for the tax year ended in 2026; or (ii) 12 months from the date of advance. An interest reserve equal to three months of interest is required and may be deducted from the advance. The term loan agreement also includes covenants requiring timely filing of SR&ED claims (within 180 days of the company's June 30 financial year-end) and maintenance of direct deposit instructions so that CRA payments are directed to the lender's account, as well as various negative covenants typical of this type of facility.

About Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining the team's considerable expertise in quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of the proprietary technology have been substantiated in 190-plus peer-reviewed publications and in 30-plus clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Its lead application, Telo-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer.

We seek Safe Harbor.